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Abstract
Background Pharmacists are important members of multidisciplinary teams but, despite surveys of provision, the role of the 
hospice pharmacist is not well described. Objective To explore the role of the hospice pharmacist and identify barriers and 
facilitators to the role. Setting Hospices offering in-patient services caring for adults towards the end of life in one geographi-
cal area of northern England. Method Pharmacists providing services to hospices were invited to take part in qualitative 
semi-structured interviews asking about experience, patient contact, team working and barriers and facilitators to the role. 
These were recorded verbatim and data were analysed thematically using framework analysis. Main outcome measure The 
hospice pharmacist’s perceptions of their role and barriers and facilitators to it. Results Fifteen pharmacists took part. Two 
themes and ten subthemes were identified focused on tasks and communication. Practise was varied and time limited the 
quantity and depth of services carried out but was often spent navigating complex drug supply routes. Participants found 
methods of communication suited to the hours they spent in the hospice although communication of data was a barrier to 
effective clinical service provision. Participants identified the need for appropriate training and standards of practice for 
hospice pharmacists would enable better use of their skills. Conclusion Barriers to the role of hospice pharmacist include 
time, access to role specific training, access to clinical information and complex medicines supply chains. The role would 
benefit from definition to ensure that hospices are able to use hospice pharmacists to their greatest potential.
Keywords Education · Hospice · Medical records · Palliative care · Patient care team · Pharmacists
Impacts on practice
• The role of the hospice pharmacist varies depending on 
the time the pharmacist works within the hospice and the 
complexity of supply chains for that hospice.
• Hospice pharmacists do not have access to role specific 
training and often have limited access to patient records 
leading to potential impacts on patient safety.
• The involvement of pharmacists in patient care has been 
proved in other settings however they are yet to fulfil 
their potential within the hospice environment.
Introduction
Hospices in the UK are usually independently run by chari-
ties with most funding coming from donations [1]. They care 
for patients with life-limiting conditions and offer symptom 
control, psychological and social support and bereavement 
care amongst other services, although each hospice has a 
unique offering. Most care (83%) is delivered in the com-
munity setting through home care, outpatient services and 
day care however, some patients are admitted for symptom 
control or inpatient care towards the end-of-life [1].
Pharmacists have been established members of the 
hospital multidisciplinary team for many years and their 
involvement in care has been shown to provide numerous 
benefits such as reduced errors, reduced readmission rates 
and increase in patient knowledge about medicines [2–5]. 
Despite this they are yet to have an established role within 
the hospice environment. A recent study shows 75% of 
UK hospices have some pharmacist provision but most of 
this is part-time with the pharmacist cover per bed below 
adequate levels [6]. In the last year of life, patients often 
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require increasing symptom control and changes to medi-
cation in terms of dose adjustments and deprescribing of 
medication for long-term conditions [7, 8].
On average, a patient in the last year of life takes 11.5 
medications reducing only to 10 at the point at which they 
die [9]. This amount of medication will inevitably lead 
to medication related problems (MRPs) (such as adverse 
drug reactions and side effects) which can be addressed by 
a pharmacist [10–12]. Involvement of pharmacists in the 
palliative care team has been shown to potentially reduce 
symptoms and side-effects and improve patient’s knowl-
edge about their medicines [12–15]. Doses of medication 
in hospices may be higher than for patients in commu-
nity settings due to severity of their illness and regimens 
are often complex [9]. Outpatients will usually manage 
medicines on their own and some may have access to 
community specialist palliative care nurses to help them 
manage their symptoms, although even patients receiving 
specialist palliative care can have MRPs that are yet to be 
addressed [11, 12].
International studies show the role of the hospice phar-
macist varies between countries, however little evidence 
exists of good quality international comparison [16]. In 
Poland, hospice pharmacists were found to have little 
clinical input and contact with patients and the role of 
hospice pharmacist (HP) was non-existent in Ukraine [17]. 
In Canada and Australia however, pharmacists conduct 
medication review within the hospice and Canadian phar-
macists routinely provide patient consultations focused 
on pain and symptom management [18]. In Canada, mul-
tidisciplinary team (MDT) working was common in the 
form of ward rounds and team meetings but less so in 
Australia and England with MDT working rare in Poland 
[6, 17–19]. All surveys where pharmacists were working 
in hospices, showed provision of information for the rest 
of the MDT was a common duty and administrative duties 
such as medicine sourcing and supply were common in the 
UK and Poland although less commonplace in Canada and 
Australia [6, 17, 18].
A number of surveys have indicated levels of hospice 
provision around the world but the HP role is yet to be 
explored [6, 17–19]. American guidelines on the essential 
and desirable activities of hospice pharmacists were pub-
lished in 2016 but it is unclear whether these have been 
adopted into practice locally or worldwide [20].
Aim of the study
The aim of this study is to explore the role of UK hospice 
pharmacists and to identify barriers and facilitators to the 
role.
Ethics approval
The study was approved by University of Leeds Medicine Eth-
ics Committee (MREC 18-065) in March 2019.
Method
Purposive sampling was carried out and pharmacists working 
in all 17 hospices from one geographical area in the north of 
England invited to take part. Contact emails or telephone num-
bers were obtained through hospice managers, hospice admin-
istration staff and local networks. Pharmacists who responded 
to this initial approach were sent a participant information 
leaflet with details about the aims of the research and consent 
form, which was provided again at the time of the interview. 
Participants were given the choice as to where the interview 
would take place as long as confidentiality was maintained. 
A semi-structured interview schedule was constructed by the 
research team based on the aims of the study and included 
background, experience, patient contact, MDT working as 
well as barriers and facilitators to the role (see Supplemen-
tary electronic material). This was then piloted with a HP and 
refined accordingly. The target sample size was 15 or when 
data saturation was reached [21].
Interviews were conducted face-to-face between July 2019 
and January 2020 by the lead author (ZE) who has a back-
ground in pharmacy and research. Interviews were conducted 
in the hospice or at the participants home (depending on their 
preference) and were audio-recorded and transcribed verbatim. 
Reflective notes were written immediately following the inter-
view to aid analysis. The interviews were semi-structured and 
this technique was employed to guide the discussions yet allow 
unexpected findings to be explored [22]. Framework analysis 
was carried out to allow comparison across participants whist 
still maintaining individual context [23]. The steps in this 
analysis were data familiarisation, construction of an initial 
coding framework, data sorting and indexing, reviewing the 
data to refine the framework followed by summary of the data 
[23]. Transcripts were read and re-read before the framework 
was developed. Two researchers (ZE and SP) coded indepen-
dently after which the framework was refined and then data 
was added to the framework. Any disagreements were resolved 
through discussion to reach an author consensus. A group dis-
cussion was held (with ZE, SP and EC) to agree concepts.
Results
Of 17 hospices in the geographical region, 16 were iden-
tified as having pharmacist provision. Fifteen pharmacists 
(covering 14 hospices) consented to interview and two did 
not respond. Fourteen were interviewed in the hospice in 
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which they worked and one in their own home. Interviews 
lasted between 30 and 55 min (mean 41.9, SD 8.5). Data 
saturation was apparent after the fifteenth interview. Demo-
graphic information is presented in Table 1 and data are 
categorised to protect anonymity. Thirteen participants were 
female and two were male. Three hospices had pharmacy 
services provided by more than one pharmacist. Most phar-
macists were employed by hospitals, one was employed by 
a tertiary trust, one by a community organisation, one by a 
wholesaler and one by a community pharmacy. Participants 
worked between 1.25 and 37.5 h per week in the hospice 
(mean 14.3, SD 13.9). Pharmacists had been in their roles 
between 3.5 months and 28 years.
Interview findings
Two overall themes were identified for HPs; task and com-
munication. Ten further subthemes were found.
Task
The HP’s role was varied, and six sub-themes were identi-
fied (see Table 2).
Medicines reconciliation
Medicines reconciliation (MR)1 was described by many 
of the participants as part of their role. Some HPs had tar-
gets of patients that should have a MR carried out by their 
service level agreement (SLA) even if they were part-time 
and there was no other pharmacist cover. Even in hospices 
which had high HP hours, full medicines reconciliation did 
not occur due to lack of around the clock provision and cover 
for annual leave meaning HPs not always being present when 
patients were admitted.
Whilst MR was structured in many hospices with targets 
and guidelines, some HPs simply did the medicines recon-
ciliation if they could fit it in with little training or guidance 
to complete it.
Knowledge transfer
Education of other staff, either formal or informal, was car-
ried out by many HPs interviewed. More established or 
experienced HPs saw this as a long-term method of aid-
ing development of other staff but also saw that it would 
be beneficial for them too; preventing errors and improving 
prescription quality. Education of staff was seen less in those 
working in low HP hours hospices, but one pharmacist did 
talk about education of patients, albeit at a low level.
Table 1  Demographic information for hospice pharmacist participants (data are grouped together to ensure anonymity)
a Other represents pharmacists employed by a community organisation, wholesaler, tertiary trust of community pharmacy
b Respondents were categorised into one of three groups based on the number of pharmacist hours: low (2–7.5 h/week), medium (8–18.75 h/
week), high (19–67.5 h/week). Categories are defined as previously described [5]
Participant Age Employer Hospice Hospice hours 
worked per  weekb
Total hospice pharmacist 
hours per  weekb
Length of time in 
role (years)
Is hospice phar-
macy their only 
role?
HP1 25–34 Hospital A High High 2 or under Yes
HP2 45–54 Hospital B High High  > 10 Yes
HP3 45–54 Hospital C High High  > 10 Yes
HP4 25–34 Hospital B & D High High and high 2 or under Yes
HP5 55–64 Othera E Low Low  > 10 No
HP6 25–34 Hospital F Medium Medium 2 or under No
HP7 35–44 Hospital G Low Low 3–9 No
HP8 45–54 Hospital G Low Low  > 10 No
HP9 35–44 Hospital D Medium High  > 10 Yes
HP10 35–44 Hospital H Low Low 3–9 No
HP11 45–54 Hospital I & J Medium Medium and medium 3–9 Yes
HP12 45–54 Othera K Low Low 2 or under No
HP13 45–54 Othera L Low Low  > 10 No
HP14 45–54 Hospital M Low Low  > 10 No
HP15 45–54 Othera N Low Low 2 or under No
1 Medicines reconciliation can be defined as “the process of accu-
rately listing a person’s medicines. This could be when they are 
admitted into a service or when their treatment changes” Care Quality 
Commission [24]Care-Quality-Commission. "Medicines Reconcilia-
tion." CQC. https:// www. cqc. org. uk/ guida nce- provi ders/ adult- social- 
care/ medic ines- recon cilia tion- how- check- you- have- right- medic ines 
(accessed 11th November, 2020).
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Table 2  Qualitative responses showing the tasks of the hospice pharmacist
Task
Medicines reconciliation
“what I do is what I call a level 2 ….so it’s a little bit more in-depth, you’re looking at the bloods, you’re looking at all you know the doctors notes and 
everything rather than just a quick interactions check which is what they had really before I started… The SLA recommends we do an 80% cover." HP6
“patients in theory are meant to have a medicines reconciliation within 24 h of admission which clearly doesn’t, can’t. I mean it happens in so 
much as the doctors do something but …because obviously I only come once a week that we obviously don’t meet that target” HP14
Knowledge transfer
“I think mentoring prescribers and supporting prescribers in their decision making and giving them confidence, educating them right, informally 
like on the job, loads of that we do.” HP2
“And so I do a little talk about managing medicines generally and inhalers and inhaler technique, spaces, washing spaces, different kind of 
devices to check if your inhalers might be working if they are worried about that and then just breathlessness. But it’s quite a low level.” HP10
“I’ve not had any formal training no so it’s kind of you know… I’ve just picked it up as I go along…done a lot of reading and stuff yeah" HP11
“probably a lot of ad hoc courses…. but they are very expensive, they are sort of aimed at err medical staff erm and the continuing professional 
development that we get paid for at the hospital means that we barely pay for 50% of any courses that we go on so then we are having to pay 
for the other 50% …they’re not something you can do very often so it has actually been quite a number of years ago" HP3
“cause we’re expected to be specialists in 2 therapeutic areas….So by definition, we’re not gonna have the same expert insight….we do have a 
level of expertise, but, it wouldn’t be the same as somebody that works full-time in hospice." HP8
Administrative duties
“I focus on audits basically…. treatment/clinic room temperature, fridge temperature, emergency boxes whether they are up to date or not, 
whether any medication needs replacing or it’s going out of date and again needs replacing and also CD cabinet check which I’m only able to 
do once a month.” HP15
“[I chair meetings] making sure that we have our up to date SOPs and anything medicines related….. the [incidents reports]..looking for trends 
and themes, err and also ….. just sort of managing how much we’re spending on medication within the hospice.” HP1
Undefined role
“I think there’s quite a lot of scope for developing the role, uhm…but like it’s time-limited on, you know, if we’re only here for say, a three-hour 
slot, half a day…what else can we develop that’s sustainable and keep the core functions that a pharmacist needs to do? “ HP12
“My duties well, my duties are very different to what the hospice wanted then but I spoke to the management and I said look, this is not do-
able…..Yes because that’s not enough time” HP15
“so [the doctor] might ring and say “I’ve got this really difficult patient at the hospice. Would you be able to pop over?”, and we would go “Yeah, 
alright.” HP8
“I suspect they’d just call if they had any problems.” HP7
“I am trying to implement SOPs …. Unfortunately, I’m a little bit behind because [my technician] has been off for like 3 or 4 months so I’m only 
working 2 ½ days it’s quite hard to get up to speed with everything but it’s all in the pipeline” HP6
“I’ve got enough time to do the minimum” HP11
“I think it’s just they’ve been more used to dealing with things in their own way here and it’s taken a long, even though I’ve been here [several 
years] it’s taken them that long to actually use me properly” HP11
“I wouldn’t be doing 2 parts of the process [prescribing and dispensing] so unless it’s an emergency or extreme sort of circumstances no, so 
that’s why the clinics [are] useful because actually if you’re prescribing in a clinic then you’re not actually dispensing because you’d be provid-
ing prescription or advice to the patient to go and get that from a registered pharmacy " HP3
Medicines sourcing
“for example, we’ve had a patient that’s just gone home this morning…. we [ordered their take-home medication] last week, then on Friday 
morning they changed, they decided to add err sodium picosulphate and then I ordered that so hopefully it was going to come on Friday after-
noon, however it didn’t get sent ‘cos they didn’t have any and she was going home at 10 o’clock this morning, so I’ve had to arrange for it to be 
ordered on an FP10 through a local pharmacy….. quite a bit of my time is more about supplies which in some ways I feel like it takes me away 
from the clinical aspects because I’m just running around trying to make sure we’ve got stuff “ HP1
“You end up spending a lot of time dealing with [stock] problems and trying to sort them out and often it’s liaising with you know maybe the 
hospital, maybe with community team or maybe a community pharmacy as well just trying to source products or find out where they’re avail-
able, maybe manufacturers as well…..Just wasting some time “ HP3
Person-centred care
“not all of them are able to talk with me very well or you know they’re resting and sometimes it’s not the most appropriate to discuss with them 
at the time" HP4
“it’s very ad hoc, it depends on the patient and what questions they might have you know if they’re very closed and they don’t really want to 
know much then you probably won’t” HP3
Interviewer: “Ok, so when would you do that prescribing?”
Participant: “In the MDT…..I mean, you could say that that’s dodgy, because you haven’t actually clocked the patient yourself, uhm…but if 
you’ve got an MDT setting, and you’ve asked all the right questions….” HP8
“Yeah it is because you don’t really know whether you need to please CQC with those audits or really be for those people" HP15
“When they go home again, I always feel like we maybe don’t provide [for them], that it would definitely be a good opportunity to give them, 
you know, [let them] ring up and say “I’ve come home and now it’s worse” HP9
“I think certainly it would be nice to spend more time actually sitting down with the patient and talking about the symptoms” HP14
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Whilst HPs contribute to education of patients and other 
members of the MDT, they still have learning needs them-
selves. Many HPs spoke of no specific training for the role 
and although some had attended a two-day multidisciplinary 
course, this was not ideal, and barriers such as time and 
costs still existed. As the HP role was often only part of their 
overall work, some participants said it was difficult to be an 
“expert” in the hospice pharmacist role.
Administrative duties
All HPs spoke of administrative duties within their roles. 
For those in low HP hours hospices, this was often focused 
on audit and was sometimes their only role within the hos-
pice. HPs often spoke of taking the lead on investigation of 
error monitoring and when time allowed were involved in 
medicines management and other interdisciplinary meetings. 
Guideline and procedural writing such as Standard Operat-
ing Procedures (SOPs) were discussed as ad-hoc roles and 
HPs were also involved, to differing extents, in the medicine 
budgets for the hospice.
Undefined role
The HP role was undefined with some HPs being unsure of 
what duties they should prioritise but also ideas of where 
they could develop the role (even though they may not have 
enough funding or time to do so). HPs were required to react 
to situations as they occurred within the hospice environ-
ment and provide assistance on demand. Many circum-
stances could not be planned for (for example new admis-
sions with difficult regimens). One HP was more passive 
in their reactivity and assumed that team members would 
contact them if they needed them.
Often pharmacists were the only one in their role in 
the hospice so when issues such as holidays or absences 
occurred, a level of resilience was needed. Part-time working 
was common with over half of the participants working 7.5 h 
a week or less within the hospice environment. This led to 
problems in service delivery and continuity.
Change seemed hard to achieve within the hospice envi-
ronment and often HPs carried on with similar duties from 
their predecessors. HP time was often utilised by duties that 
were not necessarily, in their opinion, the best use of their 
time.
HPs did talk about what difference a prescribing qualifi-
cation would bring to their role. One HP was qualified but 
did not use it, and two were, at the time of the interviews, 
training for the qualification. Issues such as safety (if they 
were writing the prescription and dispensing it) and confi-
dence for HPs in medium or low HP hours hospices were 
also discussed. Some HPs thought the prescribing qualifi-
cation would be useful but there was also some doubt as 
to whether that would force them to sacrifice other duties 
within their workload.
Medicine sourcing
All hospices had slightly different methods of sourcing med-
icines. Current issues with medicines shortages and complex 
delivery pathways often impacted on the HPs working day 
where they would have to spend time trying to source medi-
cation for patients. One hospice obtained their medicines 
from the local hospital via a tertiary hospital and had one 
delivery a day. This could lead to problems when patients 
had rapidly changing conditions. Changes to UK medication 
licencing in recent years has added to the costs and complex-
ity of hospice medication supply making once simple supply 
chains more convoluted for many hospices..
Current shortages are not always well communicated due 
to different models operating in hospices, hospitals and com-
munity pharmacies. This can lead to extra time being spent 
on obtaining patient medication.
Person‑centred care
HPs displayed person-centred care and compassion in the 
way they spoke about their role. They talked about proac-
tively tailoring care to the individual needs of the patient 
by crushing tablets when the patient could not swallow 
or organising dosette boxes for patient to go home with. 
Sometimes care was person-centred in the decision where a 
seriously ill patient was not disturbed to discuss their medi-
cation. Care was sometimes delivered in what could be con-
sidered, less person-centred ways by prescribing for a patient 
the HP had never met.
There was confusion as to how to do the right thing for 
patients whilst also working towards the priorities of man-
agers and hospice targets. One HP saw a gap in how care 
could be delivered in a more person-centred way by provid-
ing remote services for when patients have been discharged. 
When asked what they would do if they had more time in 
their roles, HPs saw person-centred care as a priority.
Communication
Communication was a common theme, and this is split into 
the different forms of communication HPs were involved 
with (see Table 3).
Routine
Regular communication with the rest of the MDT could 
occur in several ways. The MDT team meetings and ward 
rounds were both opportunities, although these had the 
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potential to take up a lot of time and did not necessarily cor-
respond with the working days and hours of the HP, particu-
larly with low and medium hours pharmacists. The meetings 
were not always perceived to be a good use of time and the 
benefits of this had to be weighed up against other priorities. 
Alternative ways of routine communication such as daily 
handovers and post ward round discussions were found to 
be useful by some participants.
Some HPs found this routine communication to be a form 
of bouncing ideas around the MDT and it was recognised 
that it may be beneficial to attend if they had additional 
hours within the hospice. One HP thought that the benefit 
of them attending the ward round was so great they opted to 
do it in their own, unpaid time.
Ad‑hoc
HPs were often required to react (as seen in undefined) but 
they are also often required to communicate in a reactive 
way. This involved answering queries from the MDT and 
this could be by phone or one of the MDT coming and find-
ing them in-person. This was seen more often from less 
experienced members of staff and there was a need to fit 
this in alongside other duties and prioritise accordingly.
Electronic/information sharing
HPs require information about the patient to safely carry out 
clinical duties. This includes current and previous medica-
tion, diagnosis history and biochemistry. In some settings 
these are carried electronically, some are paper-based and 
some are a combination. HPs had a mixture of access to 
patient information. Often it was time-consuming to find 
the relevant information about the patient and it was not 
clear whether the full picture had been obtained. The lack of 
access to medical records may be due to system failures as 
primary, secondary and tertiary care use separate systems. 
Often systems which were available were incomplete and 
did not contain records from other settings.
Networks
HPs often use networks of healthcare professionals 
to improve patient care. This may be by liaising with 
Table 3  Qualitative responses showing communication of hospice pharmacists
Communication
Routine
“I try to go on them [ward rounds], it will depend on the timing, how long they go for but if it is quite busy I will try and hang around in the 
office so I’m there for sort of the pre and post discussion of ward rounds… that could go [on] for 4 h” HP3
“[the] best [thing] about being in [this hospice], cause [the doctors] always come back in and just will discuss, and you’re just there so, you kind 
of absorb all this information, just by being there…” HP9 [talking about sharing an office with the doctors]
“I’m coming to do the ward round then……unpaid, yes.….I feel like it does help me do my round checking charts, I can actually envisage the 
patient and what’s going on with them a bit better if I’ve been on the ward round.” HP10
Ad-hoc
“we carry a phone so the doctors can contact us erm so we’re very much involved in the day to day medicines decision making…. it’s very much 
part of the MDT" HP2
“As I said if I’m in the ward office, they will just come over and ask…., on the inpatient unit people will come and knock at the door ….but 
I think it depends on the experience of the staff and what other staff are about …. Sometimes the consultants might come in and talk about 
symptoms but probably less so. HP3
Electronic/information sharing
“I very rarely get to see all the meds that they’ve come in on so it’s more a case of trying to work out what’s been going on and looking on Syst-
mOne….if they’ve got any notes, if they’ve come over from hospital I can go through the notes from hospital but sometimes it’s difficult to get 
a true record of what patients have been on…. I’ve only got nurse role [on the electronic system] which is a bit frustrating” HP11
“you get patients say here erm who have the list of medications from the GP but that isn’t kept up to date with any changes that are made by 
other teams and you get people who are sort of on a drug that is never provided by the GP and the GP doesn’t actually include that on the 
records” HP13
“it’s a case of piecing everything together you know …. I think things are not terribly joined up because everyone’s using different systems I 
think that’s the problem so you are relying on the relevant letters being printed out or received." HP14
Networks
“so sometimes [the doctors] want to start a blister pack, so I might ring the chemist and check, you know, that that was alright, discuss that with 
them and… depending on the community pharmacy, obviously, as to how much they know about the patients… and they’ll say “We’ve tried 
that in the past” or”It hasn’t worked” cause everyone thinks blister packs are amazing but, actually for our patients, you’ve still gotta pop them 
out" HP9
“cause I’ve been here so long, I guess I know most of the community nurses anyway, cause we try and train them when they’re doing their 
prescribing….I guess that’s a good thing about being here so long, isn’t it? They’re…kind of all aware.” HP9
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community pharmacists regarding individual patient needs 
at discharge regarding obtaining or dispensing medication.
Networks had also been created when the HP had been in 
their role for an extended period of time. This often meant 
that they know who to contact for which issue and this may 
make their job easier. HPs who had limited time in the hos-
pice or were not established in the hospice may find it dif-
ficult to develop the networks they need to provide the best 
care.
Discussion
This study explored the role of the hospice pharmacist in the 
UK. The findings show the varied tasks of hospice pharma-
cists and the attributes useful for the role. Challenges were 
shown in communication, knowledge, sourcing medicines 
and general time pressures with most HPs working part-
time. This is the first study to qualitatively explore the role 
of a HP, although some surveys have been conducted con-
cerning duties, hours and MDT working [6, 17–19]. Our 
main findings concur with a previous study in 1995 of HPs 
performing administrative, clinical, educational and supply 
however the role of the pharmacist now encompasses much 
more in terms of clinical duties than was expected 25 years 
ago [25].
Lack of time was an issue that was talked about frequently 
in the interviews as has been found elsewhere [18]. Eleven of 
the fifteen HPs interviewed worked less than 19 h a week in 
the hospice, which is similar to the results of a 2020 survey 
of UK hospice pharmacists showing a mean HP working 
week of 13 h [6]. HPs talked of scope for more person-
centred services if they had time, and where time was less 
of a problem, they had a more integral role in training and 
development of other staff. Surveys in Poland, Australia 
and Canada showed part-time working to be by far the most 
common model of HP provision [17, 18]. Administrative 
duties were common and those working less hours often 
described more of an administrative role with audit and error 
reporting. HP prescribing in the hospice environment was 
being considered although may only be useful and safe for 
those working longer hours.
Lack of time was further adversely affected by current 
medicines shortages and time spent sourcing medicines. 
Issues have been compounded by sometimes complex 
sourcing pathways which may have been brought about by 
licencing changes in the UK [26]. Although hospices are 
usually funded by charities, medicine budgets are provided 
by the NHS meaning expensive government licences to 
obtain supplies from local hospitals are being paid for out of 
NHS budgets. The complex supply chains often involved in 
obtaining medicines for hospices is an unnecessary drain on 
resources. Although UK HPs have a major role in medicines 
sourcing, this is not the same in all countries [16, 18]. Time 
taken in sorting out issues was sometimes negated by HPs 
who had been in their role for a long time or were experi-
enced in the field as they could use their networks to achieve 
what they needed to more quickly.
HPs showed person-centredness in many ways, from 
unpaid working to provide a more complete service to tai-
loring the service provided to the individual needs of the 
patient. Poland relies more heavily on unpaid hospice phar-
macist time although they rarely have direct involvement 
in patient care [17]. In a recent review, HPs were found to 
have a more person-centred role in USA, UK, Australia and 
Canada compared with the rest of the world [16]. Person-
centred care for patients at the end of life has been integrated 
into guidelines relating to care for this specific patient group 
[27, 28]. Although most HPs demonstrated this, some had 
different ideas about how to best use their time to improve 
patient care.
HPs in high HP hours hospices provided support to 
the wider MDT in the form of training and mentoring as 
seen elsewhere [16, 18]. Patient consultations were rarely 
described, in contrast with practice in Canada, although 
this may be due to differences in terminology as when car-
ried out on admission this may be referred to as medicines 
reconciliation [18]. Those in lower HP hours hospices also 
added value in terms of medicine rationalisation and medi-
cines specific knowledge however no HP is able to access 
pharmacist-specific palliative care training as available train-
ing is all multidisciplinary [6]. Lack of pharmacists with 
relevant skills has been found to be an issue elsewhere and 
other barriers identified to HP training include cost and time 
[18]. The HP role is yet to be defined and often participants 
had to work out how best to use the time they had in the hos-
pice to benefit patients. Although service level agreements 
were in place in some hospices, there would be benefit from 
defined role objectives which were achievable and evidence-
based. Guidelines on essential and desirable activities of 
HPs from the USA show some correlation with these find-
ings, although the varied nature of time and training lead to 
large inconsistencies in practice [18, 20].
Communication of information was a key facilitator to the 
HP’s role. HPs had often developed methods of regular and 
ad-hoc communication with members of the MDT (depend-
ing on how much time they had) to pass-on or receive rel-
evant information. The provision of information to the MDT 
was found to be commonplace as has been found elsewhere 
[16–19]. Lack of full access to patient records leads to time 
wasted piecing together information from different sources. 
A recent survey showed that only 12% of hospice pharma-
cists had full read and write access to the patient’s medical 
records which could have potential safety implications when 
a complete patient history is important for medicines recon-
ciliation to be effective [6, 29].
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The results of this study have led to the development of 
a list of barriers and facilitators for the role of HP. Barri-
ers include lack of time, role-specific training, definition of 
role, complex supply chains and lack of access to full patient 
records. Facilitators would therefore include investment in 
HP time, training, role definition, efficiencies in supply 
chains and access to full patient records. These facilitators, 
if addressed may positively influence the role the HP plays 
within the hospice allowing the HP to help fulfil their poten-
tial as an integral member of the MDT. The facilitators will 
each require further research to quantify and explore their 
individual components.
Strengths and limitations
This study was reliable as it could be replicated easily, and it 
is likely that consistent results would be obtained. Although 
the study was carried out in one geographical region of the 
UK, this was a large area with diverse populations and 
healthcare systems making it likely to have transferability. 
Although one researcher was responsible for conducting the 
interviews, researcher bias was addressed by the inclusion of 
other members of the research team in the analysis.
Interviews could be carried out on a national scale to 
confirm transferability and an international scale to identify 
practice elsewhere. Further research into effective and effi-
cient hospice medicines supply is required. The UK would 
benefit from research to develop models for low, medium 
and high HP hours hospices to develop role guidance to 
ensure optimum use of resources.
Conclusion
Although pharmacists have been present in hospices for dec-
ades, it is only now becoming apparent, the added value they 
could provide through their clinical expertise in medicines. 
HPs provide varying duties and this is often dependent on 
the time available in the role or the duties that have been 
historically carried out by the HP. Investment in training and 
definition of roles along with improvement of supply chains 
and communication systems will facilitate HPs to fulfil their 
true worth to hospice care at the end of life.
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